Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)
Excerpt from the Press Release:
HANGZHOU, China and SAN FRANCISCO, April 13, 2022 /PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of subject dosing in its Phase 1 clinical trial of XW004. XW004 is an oral tablet formulation of Ecnoglutide, a novel long-lasting GLP-1 peptide analogue under development for the treatment of obesity, type 2 diabetes and NASH. Co-formulation of the peptide agonist with an oral absorption enhancer prevents deactivation in the digestive tract and allows for daily oral administration. Preclinical studies have demonstrated good safety and efficacy profiles for XW004.
The single-center, double-blind, placebo-controlled, and multiple ascending dose (MAD) study will evaluate XW004 at doses of up to 30 mg daily in approximately 56 healthy volunteers. Participants in the trial, which is being conducted in Australia, will be treated with the study drug once daily for 15 days with a 21-day treatment-free follow-up period. The objective of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW004.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?